Oral corticosteroids present significant long-term risks with uncertain evidence for improving asthma outcomes, according to data presented at the American College of Allergy, Asthma & Immunology ...
* Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma - ...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...
The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...
The US FDA has approved depemokimab as an add-on maintenance therapy for individuals aged 12 years or older with severe asthma, according to a press release from manufacturer GlaxoSmithKline.
Zacks Investment Research on MSN
GSK's Exdensur gets FDA nod for severe asthma treatment
GSK plc GSK announced that the FDA has approved Exdensur (depemokimab-ulaa), an ultra-long-acting IL-5–targeting biologic, as ...
The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.
A monthly injection could help people with severe asthma come off daily steroid tablets entirely without any impact on symptoms, a trial has found. Tezepelumab – also known as Tezspire and made by ...
Please provide your email address to receive an email when new articles are posted on . Data came from the FDA Adverse Event Reporting System from 2004 to 2024. Omalizumab had significant associations ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A one-time subcutaneous administration of GB-0895 ...
Symbicort, which is used to treat chronic obstructive pulmonary disease and asthma, can cause side effects. Mild side effects include nasal congestion and headaches. Serious side effects include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback